|
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NOT_RECRUITINGPhase 3Sponsored by Novartis Pharmaceuticals
No longer actively recruiting
PhasePhase 3
SponsorNovartis Pharmaceuticals
Started2026-05-11
Est. completion2030-01-09
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
Locations124 sites
View on ClinicalTrials.gov →
NCT07517263
Summary
This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blind parent study (CTQJ230A12301).
Eligibility
Age: 18 Years – 100 YearsHealthy volunteers accepted
Inclusion Criteria: * Participants who have provided informed consent prior to initiation of any study-specific activities/procedures. * Participants who have completed the parent study EOS visit while still on assigned investigational product. Exclusion Criteria: * Participants who for any reason permanently discontinued or have interrupted the investigational product for continuous 6 months at EOS during the parent study. * Participants who have a history or evidence of any clinically significant disorder, condition, or disease that in the opinion of the investigator or Novartis physician (if consulted), would put the participant at risk or interfere with the study participation, including, but not restricted to conditions outlined in Table 6-3 and Table 6-5. * Participants are receiving another investigational drug or device before the open-label treatment period. * Participants have a known sensitivity to the study drug and are deemed as unsuited for the study by the Investigator at Screening visit. Other protocol-defined inclusion/exclusion criteria may apply.
Conditions2
Cardiovascular Disease and Lipoprotein(a)Heart Disease
Interventions1
Locations124 sites
SEC Clinical Research LLC
Heart Center Research Llc
Mercy Gilbert Medical Center
Clinical Research Inst of Arizona
Find trials near these locations
All trials in AlabamaAll trials in ArizonaAll trials in ArkansasAll trials in CaliforniaAll trials in ColoradoAll trials in ConnecticutAll trials in FloridaAll trials in GeorgiaAll trials in IllinoisAll trials in IndianaAll trials in IowaAll trials in KansasAll trials in LouisianaAll trials in MaineAll trials in MarylandAll trials in MassachusettsAll trials in MichiganAll trials in MinnesotaAll trials in MississippiAll trials in MissouriAll trials in NebraskaAll trials in New HampshireAll trials in New JerseyAll trials in New YorkAll trials in North CarolinaAll trials in OhioAll trials in PennsylvaniaAll trials in South DakotaAll trials in TennesseeAll trials in TexasAll trials in UtahAll trials in VirginiaAll trials in WashingtonAll trials in West VirginiaAll trials in Wisconsin
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 3
SponsorNovartis Pharmaceuticals
Started2026-05-11
Est. completion2030-01-09
Eligibility
Age18 Years – 100 Years
Healthy vol.Accepted
Locations124 sites
View on ClinicalTrials.gov →
NCT07517263